| Literature DB >> 31167365 |
Larissa Monteiro Costa Pereira1, Felipe J Aidar2,3,4,5,6, Dihogo Gama de Matos7, Jader Pereira de Farias Neto8,9, Raphael Fabrício de Souza10, Antônio Carlos Sobral Sousa11, Rebeca Rocha de Almeida12, Marco Antonio Prado Nunes13, Albená Nunes-Silva14, Walderi Monteiro da Silva Júnior15,16.
Abstract
Obesity is a highly prevalent chronic metabolic disease, with an increasing incidence, and is currently approaching epidemic proportions in developing countries. Ouraim was to evaluate the activity levels, quality of life (QoL), clinical parameters, laboratory parameters, and cardiometabolic risk factors afterbariatric surgery (BS). We classified78 patients who underwentBS into four groups, as follows: Those evaluated 1-2 years after BS (BS2), 2-4 years after BS (BS4), 4-6 years after BS (BS6), and 6-10 years after BS (BS+6). Body weight (BW), body mass index (BMI), comorbidities associated with obesity (ACRO), physical activity level, and QoL were evaluated. Patients exhibited improvements in BW, BMI, cardiometabolic risk, hypertension, dyslipidemia, and diabetes and significant changes in lipid profiles in the first postoperative yearafter BS.The physical activity level inthe BS2, BS4, and BS6 groups was increased, compared with that in the first postoperative year, with a decrease in International Physical Activity Questionnaire scores at 1 year in the BS2 (207.50 ± 30.79), BS4 (210.67 ± 33.69), and BS6 (220.00 ± 42.78) groups. The QoL of patients in theBS2 and BS4 groups was excellent and that of patients in the BS4 and BS+6 groupswas very good. These findings suggest that BS promoted improved physical activity levels and QoL and reduced comorbidities in patients with morbid obesity.Entities:
Keywords: bariatric surgery; health; physical activity; quality of life
Mesh:
Year: 2019 PMID: 31167365 PMCID: PMC6603870 DOI: 10.3390/ijerph16111975
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Study design. BS: Bariatric Surgery, IPAQ: International Physical Activity Questionnaire, BAROS: Bariatric Analysis and Reporting Outcome System Questionnaire, Anthropometry: weight (kg), height (cm), waist circumference (cm) (HDL, LDL), triglycerides, fasting glycemia (at four time points: admission, release, postoperative, and final), ACRO: Evaluation of Comorbidities Associated with Obesity.
Distribution of patients in the groups (mean ± standard deviation) (Male: ♂, Female: ♀).
| BS 2 Years | BS 4 Years | BS 6 Years | BS+6 Years | |
|---|---|---|---|---|
| Age | 45.0 ± 11.0 | 37.0 ± 6.6 | 40.0 ± 11.7 | 40.0 ± 9.0 |
| Age—♂ | 46.0 ± 4.0 | 36.0 ± 6.9 | 37.0 ± 12.8 | 39.0 ± 9.4 |
| Age—♀ | 45.0 ± 11.5 | 36.0 ± 5.6 | 40.0 ± 11.7 | 40.0 ± 9.0 |
| Gender ♂(%)/♀(%) | 2(16.7)/10(83.3) | 5(35.7)/9(64.3) | 3(13.6)/19(86.4) | 8(26.7)/22(73.3) |
Note: Age refers to the time between surgery and the present time.
Evaluation of obesity-related comorbidities (ACRO).
| ACRO Score | Description |
|---|---|
|
| |
| 0 | Absence |
| 1 | Glucose intolerance |
| 2 | Diabetes mellitus (diagnosed) |
| 3 | Controlled with oral antidiabetic |
| 4 | Insulin therapy |
| 5 | Clinical complications |
|
| |
| 0 | Absence |
| 1 | Borderline (200–239 mg/dL) |
| 2 | Conventional control (diet + physical activity) |
| 3 | Single medicinal product |
| 4 | Multiple medication |
| 5 | Uncontrolled |
|
| |
| 0 | Absence |
| 1 | Borderline (systolic: 130–139 mmHg, diastolic: 85–89 mmHg) |
| 2 | Conventional control (diet + physical activity) |
| 3 | Single medicinal product |
| 4 | Multiple medication |
| 5 | Uncontrolled |
Differences in weight, waist circumference, body mass index, percentage of excess weight loss, physical activity level, and quality of life between the groups (mean ± standard deviation).
| BS2 | BS4 | BS6 | BS+6 |
|
| |
|---|---|---|---|---|---|---|
| Admission weight | 124.8 ± 24.6 a | 127.1 ± 21.0 a | 111.6 ± 21.8 a | 143.8 ± 29.3 a | ||
| Preoperative weight | 120.5 ± 21.7 a | 120.7 ± 15.6 a | 108.8 ± 22.4 | 134.3 ± 29.6 a | ||
| Postoperative weight | 111.8 ± 19.1 | 116.4 ± 14.0 | 101.6 ± 23.0 | 124.5 ± 28.4 a | ||
| Current weight | 83.5 ± 21.1 ab | 85.4 ± 10.1 ab | 77.3 ± 16.5 ab | 97.2 ± 25.1 | ||
| Minimum weight | 83.5 ± 21.2 ab | 83.8 ± 12.0 ab | 75.8 ± 17.2 ab | 94.1 ± 24.3 ab | 0.001 | 0.458 # |
| IPAQ Admission | 135.00 ± 27.47 | 134.67 ± 24.75 | 151.67 ± 25.66 | 109.67 ± 27.98 | ||
| IPAQ after 1 year | 207.50 ± 30.79 a | 210.67 ± 33.69 ab | 220.00 ± 42.78 ab | 197.67 ± 58.70 a | ||
| Current IPAQ | 189.17 ± 28.43 | 162.67 ± 29.63 | 193.33 ± 45.64 | 172.67 ± 53.24 | 0.001 | 0.438 # |
p < 0.05 (one-way ANOVA and post-hoc Bonferroni test). # Large effect. a: Different compared with other time points within the groups (p < 0.001). b: Different compared with other groups and time points (p < 0.001).BS2: Up to 2 years after BS; BS4: Up to 4 years after BS; BS6: Up to 6 years after BS; BS+6: More than 6 years after BS.
Figure 2Percentage of excess weight loss (PEWL) in the different groups.
Figure 3Waist circumference (WC) in the different groups (p < 0.001, f2 of Cohen = 0.356).
Figure 4Body mass index in the different groups (p < 0.001, f2 of Cohen = 0438).
Figure 5Quality of life in different groups (p = 0.049, f2 of Cohen = 0.099).
Biochemical marker levels in the groups.
| BS2 | BS4 | BS6 | BS+6 |
|
| |
|---|---|---|---|---|---|---|
| HDL Admission | 42.33 ± 7.74 | 43.80 ± 13.49 | 42.38 ± 14.48 | 41.40 ± 9.82 | ||
| HDL Release | 45.17 ± 9.61 | 42.09 ± 10.40 | 48.31 ± 14.57 | 43.13 ± 8.87 | ||
| HDL post BS | 40.67 ± 9.23 | 42.07 ± 12.33 | 42.05 ± 12.68 | 47.30 ± 12.86 | ||
| HDL Final | 47.92 ± 14.96 | 47.87 ± 9.45 | 49.19 ± 12.03 | 44.17 ± 12.13 | 0.098 | --- |
| LDL Admission | 120.32 ± 42.81 | 117.32 ± 39.52 | 14135 ± 41.23 a | 120.49 ± 25.02 | ||
| LDL Release | 110.58 ± 26.43 | 111.25 ± 38.70 | 124.17 ± 37.51 | 118.90 ± 30.75 | ||
| LDL post BS | 104.92 ± 28.19 | 117.47 ± 23.47 | 110.24 ± 29.11 | 109.37 ± 25.07 | ||
| LDL Final | 90.42 ± 17.31 ab | 93.40 ± 17.20 ab | 111.95 ± 29.99 | 85.71 ± 22.86 ab | 0.003 | 0.153 # |
| Cholesterol Admission | 189.25 ± 33.27 | 195.07 ± 40.57 | 227.00 ± 38.49 a | 187.90 ± 32.13 | ||
| Cholesterol Release | 178.92 ± 22.85 | 178.90 ± 31.53 | 197.60 ± 18.74 | 185.93 ± 34.19 | ||
| Cholesterol post BS | 153.92 ± 21.99 ab | 162.27 ± 38.45 | 171.71 ± 31.94 | 180.60 ± 35.45 | ||
| Cholesterol final | 155.50 ± 18.79 a | 156.47 ± 28.68 | 171.95 ± 35.04 | 146.50 ± 34.30 a | 0.001 | 0.234 # |
| Triglycerides Admission | 150.80 ± 33.94 | 164.40 ± 38.33 | 139.43 ± 20.09 | 152.35 ± 57.67 | ||
| triglycerides Release | 130.42 ± 25.67 | 132.86 ± 30.65 | 118.85 ± 18.07 | 141.97 ± 68.16 | ||
| triglycerides post BS | 92.33 ± 14.11 | 95.60 ± 31.45 | 99.52 ± 24.13 | 126.30 ± 41.03 | ||
| triglycerides Final | 87.42 ± 24.44 ab | 80.47 ± 12.51 ab | 79.86 ± 16.82 ab | 85.50 ± 31.99 ab | 0.001 | 0.196 # |
| Blood glucose Admission | 103.75 ± 32.52 | 101.84 ± 30.60 | 100.43 ± 20.46 | 106.40 ± 37.73 | ||
| Blood glucose Release | 111.17 ± 45.71 | 109.83 ± 27.31 | 89.50 ± 12.58 | 93.13 ± 17.62 | ||
| Blood glucose post BS | 92.58 ± 16.62 | 83.20 ± 7.85 | 86.10 ± 10.74 | 90.83 ± 25.60 | ||
| Blood glucose Final | 95.33 ± 21.27 | 82.73 ± 11.29 | 82.48 ± 8.48 | 79.57 ± 7.51 ab | 0.039 | 0.109 * |
p < 0.05 (one-way ANOVA and post-hoc Bonferroni test). * Small effect, # Large effect. a: different compared with other timepoints within the groups (p < 0.001). b: Indicates a difference in relation to the other groups and time points (p < 0.001).BS: Bariatric surgery; BS2: Up to 2 years after bariatric surgery; BS4: Up to 4 years after bariatric surgery; BS6: Up to 6 years after bariatric surgery; BS+6: More than 6 years after bariatric surgery, Rel: Released after 3 months of treatment.
Frequency of comorbidities (diabetes, dyslipidemia, and hypertension) over time in the groups, according to the ACRO score (≤2.0).
|
|
|
|
|
|
|
|
| BS2 | 12 | 6 | 6 | 10 | 11 | 11 |
| BS4 | 14 | 12 | 11 | 13 | 13 | 13 |
| BS6 | 22 | 18 | 20 | 21 | 21 | 22 |
| BS+6 | 30 | 21 | 22 | 30 | 30 | 30 |
|
|
|
|
|
|
|
|
| BS 2 | 12 | 6 | 7 | 10 | 11 | 12 |
| BS 4 | 14 | 12 | 11 | 14 | 14 | 14 |
| BS 6 | 22 | 14 | 16 | 20 | 20 | 20 |
| BS +6 | 30 | 11 | 13 | 28 | 29 | 30 |
|
|
|
|
|
|
|
|
| BS 2 | 12 | 1 | 1 | 7 | 7 | 8 |
| BS 4 | 14 | 9 | 4 | 10 | 12 | 13 |
| BS 6 | 22 | 9 | 11 | 17 | 18 | 18 |
| BS +6 | 30 | 7 | 7 | 26 | 26 | 26 |
BS: Bariatric Surgery; The numbers represent the frequency and number of diagnosed subjects in each comorbidity over time [32].